ArticleHaematologica2022
Prospects in the management of patients with follicular lymphoma beyond first-line therapy.
Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.Blood advances · 2024Trial
- Trial
- Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States.Future oncology (London, England) · 2026Article
- A Phase II Study ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab-bendamustine in follicular lymphoma: a single-center case series study.Journal of cancer research and clinical oncology · 2025Observational
- Bruton's Tyrosine Kinase Inhibitors: A Versatile Therapeutic Approach for Cancer, Autoimmune Disorders, GVHD and COVID-19.Mini reviews in medicinal chemistry · 2025Review
- A Rare Diagnosis of Parotid Gland Follicular Lymphoma Arising in Warthin Tumor: Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.Journal of the advanced practitioner in oncology · 2024Review
- Preferences of patients and physicians in the United States for relapsed/refractory follicular lymphoma treatments.Cancer medicine · 2024Article
- Article
- Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma.The Journal of international medical research · 2024Article
- The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy.Frontiers in oncology · 2024Review
- CAR-T Cell Therapy for Follicular Lymphomas.Mediterranean journal of hematology and infectious diseases · 2024Review
- Unraveling the complexity of follicular lymphoma: insights and innovations.American journal of cancer research · 2024Review
- Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis.Cancers · 2023Article
- Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.Clinical lymphoma, myeloma & leukemia · 2023Article
- A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.Expert review of anticancer therapy · 2023Article
- Advances in the multi-omics landscape of follicular lymphoma.International journal of biological sciences · 2023Review
- Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review.Frontiers in oncology · 2023Review
- Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab.Cancer management and research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The management of patients with relapsed or refractory follicular lymphoma has evolved markedly in the last decade, with the availability of new classes of agents (phosphoinositide 3-kinase inhibitors, immunomodulators, epigenetic therapies, and chimeric antigen receptor T cells) supplementing the multiple approaches already available (cytotoxic agents, anti-CD20 antibodies, radiation therapy, radioimmunotherapy, and autologous and allogeneic transplants). The diversity of clinical scenarios, the flood of data derived from phase II studies, and the lack of randomized studies comparing treatment strategies preclude firm recommendations and require personalized decisions. Patients with early progression require specific attention given the risk of histological transformation and their lower response to standard therapies. In sequencing therapies, one must consider prior treatment regimens and the potential need for future lines of therapy. Careful evaluation of risks and expected benefits of available options, which vary depending on location and socioeconomics, should be undertaken, and should incorporate the patient's goals. Preserving quality of life for these patients is essential, given the likelihood of years to decades of survival and the possibility of multiple lines of therapy. The current landscape is likely to continue evolving rapidly with other effective agents emerging (notably bispecific antibodies and other targeted therapies), and multiple combinations being evaluated. It is hoped that new treatments under development will achieve longer progression-free intervals and minimize toxicity. A better understanding of disease biology and the mechanisms of these different agents should provide further insights to select the optimal therapy at each stage of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.